Thank you for your interest in submitting your manuscript to the Journal of Drugs in Dermatology.

Submissions should be submitted to http://JDD.msubmit.net 

You can view the guidelines for creating an account and submitting your manuscript files under the “For Authors” section of the Electronic Journal Press (eJP) submission portal. 

Please review all of the following before submitting your manuscript

JDD Artificial Intelligence (AI) Ethics Policy
Duplicate Publication, Redundant Publication
Limited Copyright Transfer Agreement
Submission Guidelines

• Submission Category Types
• Manuscript preparation
• Title Page
• Abstract
• Inline Citations
• Figures, Tables, Images
• Disclosure Statements
• References
• Manuscript Status Updates

AI-based tools must be disclosed and clearly explained in all Journal of Drugs in Dermatology publications. Authors should clearly state the use of AI-based tools in their Disclosure statement upon submission.

Scholarly works must be the author’s own. Authors are accountable for their research papers’ validity, integrity, and originality.

In order to proceed with the peer review process, the Submitting Author must complete and electronically sign the Limited Copyright Transfer Agreement. This form is required to complete the submission process. This form transfers copyright from authors to the Journal of Drugs in Dermatology only if the submission has been accepted for publication. 

Submission Category Types
The Journal of Drugs in Dermatology (JDD) offers a range of submission categories to accommodate diverse content types, from original research and clinical case reports to expert opinion pieces and concise communications. Each article type has specific scope, word count, and formatting requirements designed to maintain the quality and relevance of content for our readership. Authors are encouraged to review these guidelines carefully to ensure their submission aligns with the appropriate category. In addition to traditional peer-reviewed sections, JDD offers invited content opportunities such as News, Views, and Reviews, and Pipeline Previews, which highlight early-stage innovations and clinical trial updates. Select content types may be published online only to ensure timely dissemination while accommodating print space limitations.

*JDD does not review pre-submissions. We encourage all subject matter related to dermatology to be formally submitted for review through our http://JDD.msubmit.net  

Please note that word count includes Abstract, Body, References, Tables, Figure legends, etc. If you exceed these limits, please provide a rationale in the cover letter. 

Supplemental Materials
The JDD does not host or publish supplemental materials. This includes any multimedia files (ie, .mov files), or additional tables or figures as PDFs. If supporting material is pertinent to your manuscript, please include inline, adhering to the word count. 

Online-Only Publication Policy
At the discretion of the editorial board, the following categories—Editorials, Research Letters, Letters to the Editor, Brief Communications, and Case Reports—may be published exclusively in the online version of the journal. This decision will be based on considerations such as the content’s relevance to a broader or more specialized audience, space limitations within the print edition, and the overall editorial strategy for the issue. All online-only content pieces are unlocked to all users, so the HTML and PDF downloads are accessible without having to log in to JDDonline.com. 

Articles published online only, will appear in the Table of Contents of the assigned printed issue, linked by a QR code for direct access. The e-only articles will appear digitally within the Journal of Drugs in Dermatology electronic (eJDD) issue, will be assigned an individual article citation, and will continue to be indexed on PubMed. For inquiries regarding the citation details, please contact editorial@jddonline.com.

Manuscripts Preparations According to JDD Style Guidelines

File Type
Microsoft Word is the preferred document format for manuscripts. 

Document Formatting
Please prepare your manuscript according to the following:

• Do not use Endnotes or Footnotes for inline citations
• Left justification; Times New Roman, font size 14, double spaced. 
• No line numbers
• In accordance with AMA style guidelines, section headers should be formatted in bold or bold italics, but not in all capital letters. Consistent formatting should be maintained throughout the manuscript.

Title Page
Manuscript titles should be ≤ 15 words.

A title page is to be provided and should include the title of the article, author names, highest level medical degrees, and author affiliations. 

The affiliation should designate the department, institution (university or company), city, and state (or country). Please use alphabetic superscripts between authors and their affiliations. 

Samantha Smith MD,^a Tom Lin MD,^b Susan Hasner PhD^a

^aDepartment of Pharmacology, University of Oklahoma, Oklahoma City, OK
^bDepartment of Dermatology, University of Ohio, Athens, OH

For administrative purposes, the title page should include the telephone number and e-mail address of the corresponding author authorized to review proofs or confirm revisions, if necessary. 

The title page must also disclose any potential perceived conflicts of interest or financial relationships relevant to the content. If there is nothing to disclose, please state so.

Please also include ~5 relevant keywords on the title page. 

Abstract
An abstract is to be provided, ≤ 250 words. 

Inline Citations (related to References)
Do not use Endnotes or Footnote utilities, as manuscripts using these will be returned to authors for reformatting. 

Inline references should only appear as superscripts:

• Superscript appearing after punctuation: a comma,¹ or a period.² 
• Superscript appearing before inline references for colons⁴: and semicolons⁴;

Figures, Photographs, and Tables Specifications

All illustrations must be complete and final, ie, publication-ready. All figures and photographs should be submitted as separate files in their source application; do not embed figures in a text document; do not submit tables as JPEGs. 

Patient Consent and Identifiable Information

Authors must protect patient privacy in all submissions. Identifiable details—including names, initials, or recognizable images—should not be included unless scientifically essential and written informed consent has been obtained. Authors are responsible for securing and retaining this consent and must provide documentation upon request. Failure to comply may result in rejection or retraction of the manuscript.

Figures/drawings: Submit graphs and drawings in TIFF, JPEG, PDF, or PPT format.

Photographs: JPEG is the preferred format for photographs; resolution 300 dpi or higher; CMYK or grayscale color space; image size at least 3.5″ wide. Identify the figure number and the corresponding author in the filename.

Tables: Preferred format is Microsoft Word or Excel. Do not embed the table as an image.

Referencing Figures, Photographs, and Tables in Manuscript
All illustrations (photographs, drawings, diagrams, tables, and charts) are each to be numbered in 1 consecutive series of Arabic numerals (eg, Figures 1 and 2; Tables 1 and 2). 

Figure legends (sentence case) and Table titles (capitalized) should be listed sequentially at the end of the main document. 

(ie) Figure 1. This is an example of psoriasis.
       Figure 2. This is another example of psoriasis. 

(ie) Table 1. Results of Clinical Study A
       Table 2. Results of Clinical Study B

Disclosure Statements
The JDD disclosure policy is for authors to provide relevant, full-detailed conflict of interest disclosures. Authors should disclose any relevant commercial or proprietary interests in any drug, device, method, product, or equipment mentioned in the submission or if there are any other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, the submitted work. If at any time, they received payments or services from a third party for any aspect of the submitted work, including grants, personal fees, non-financial support, or other conflicts of interest, it should be stated. Authors understand and agree that such disclosure will identify any financial interest in any items mentioned in the submission.

For each author, a statement that mentions any potential perceived conflicts of interest and/or relevant financial relationships should be included under the heading of Disclosure, or it should be stated if the author has no conflicts. 

Conflict of interest statements should be submitted in complete statement format (ie, no lists). Example: Tom Smith MD is a consultant for Company A, Company B, and Company C. Barbara Lane PHD has no conflicts of interest to disclose. 

References
Following the AMA Manual of Style 11th Edition, each reference should be cited in the text with a superscript Arabic numeral after punctuation, and corresponding to the numeral listed sequentially in the reference list at the end of the article (eg, as shown in the prior study.1). 

If there are more than 4 authors for a reference, list the first 3 followed by et al. in accordance with the punctuation below. Do not use the Endnotes or Footnotes function in Microsoft Word.

Most citations appear in AMA form on PubMed, which can be copied and pasted into your manuscript’s reference section. 

Book
Authors (up to 3, then et al.). Title of book. Edition. State: Publisher. Year.
Goodman A, Goodman L, Gilman A. The Pharmacologic Basis of Therapeutics. 6th ed. New York: Macmillan. 1980.

Chapter in a Book
Authors (up to 3, then et al.). Title of chapter. In: editors. Title of book. Edition. City, State: Publisher. Year: pages
Pathak M, Fitzpatrick T. Preventative treatment of sunburn, dermatophilosis, and skin cancer with sun-protective agents. In: Fitzpatrick T, Eisen A, Wolffe K, eds. Dermatology in General Medicine. 4th ed. New York, NY: McGraw-Hill. 1993:1689-1717.

Journal Article
Authors (up to 3, then et al.). Title of article. Journal Abbreviation. Year;Volume (Issue):Pages
Ito T, Moore JI, Koss MC. Topical application of CO2 increases skin blood flow. J Invest Dermatol. 1989;93:259-262.

Package Insert
Product [package insert]. City, State: Distributor/maker; year.
Lamasil [package insert]. East Hanover, NJ: Sandoz PharmaceuticalsCorp; 1993.

Poster Presentation
Authors (up to 3, then et al.). Title of article. Poster presented at: Name of Symposium. Month, Year, City, State/Country.
Passeron T, Kerob D, Le Dantec G, et al. Comparison of 2-MNG-containing depigmenting serum vs. hydroquinone 4% in the treatment of facial melasma: a monocentric randomized controlled study. Poster presented at: EADV Congress 2024. September 2024, Amsterdam, Netherlands. 

Website
Name of Website. Title of Article. Available at: Link. Accessed Month (spelled out), Day, Year.
National Psoriasis Foundation. Statistics. Available at: http://www.psoriasis.org/about/stats/. Accessed July 17, 2006.

Note: Use of the aforementioned style guides does not signify an endorsement of said products. Please do your best to follow the instructions herein, or your submission may be rejected.

Manuscript Status Updates
For status updates on submitted manuscripts, please view the ‘Where Is My Paper?’ diagram here. If this does not answer your question, please reach out to the Editorial Department. Thank you. 

All submissions undergo a blind peer review conducted by at least two members of our Editorial Board. Prior to peer review, each manuscript is evaluated for adherence to the author guidelines. Please allow at least 4-6 weeks for a decision.